October 27, 2020 – Thermo Fisher Scientific announced it has expanded its Direct-to-Patient service offering that supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates.
The offering now includes Clinical Site-to-Patient, Pharmacy-to-Patient and Depot-to-Patient services to enable clinical trial medication delivery directly to patients’ homes.
Thermo Fisher Scientific’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched earlier this year to ensure clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic.
Thermo Fisher Scientific says that the program can support any trial phase and a range of trial variables including Interactive Response Technology (IRT) systems, blinded/unblinded and home nursing providers. Clinical Site-to-Patient services are available in 47 countries and have supported more than 1,500 shipments to patients worldwide to help treat more than 25 different indications.
Direct-to-Patient also offers end-to-end cold chain management and traceability and centralized storage of clinical trial material, reducing waste and minimizing the storage space needed at clinical sites.